**Specifications table**TableSubject area*Medicine*More specific subject area*Hypertriglyceridaemia*Type of data*Text file, Table*How data was acquired*Retrospectively. Clinical history and genotyping of patients*Data format*Summary of raw data*Experimental factors*Retrospective analysis of patient records*Experimental features*The cut-off for the familial chylomicronaemia syndrome score was determined from a validation cohort and tested on replication cohorts*Data source location*Lyon, France; Montréal, Canada; Rome, Italy; Palermo, Italy*Data accessibility*Data are within this article*

**Value of the data**•Summary data from relatively large cohorts of familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS) patients.•The data illustrate how a cut-off level of ≥10 for the FCS clinical diagnostic score [@bib1] may help to differentiate between FCS and MCS patients.•The data provide a benchmark for future studies.

1. Data {#s0005}
=======

The familial chylomicronaemia syndrome (FCS) cohort included 25 patients with FCS from the Montreal lipid clinic and four patients from the Lyon lipid clinic ([Table 1](#t0005){ref-type="table"}). The multifactorial chylomicronaemia syndrome (MCS) cohort included 29 patients consecutively studied over the previous 2 years in the Lyon lipid clinic ([Table 1](#t0005){ref-type="table"}). The FCS cohort was used to establish sensitivity and the MCS cohort was used to establish specificity, leading to a receiver operating characteristic (ROC) curve area of 0.91 [@bib1]. Replication of the diagnosis capacity of the FCS score was retrospectively tested in two additional lipid clinics. The Rome replication cohort included 16 patients with FCS and 15 patients with MCS ([Table 1](#t0005){ref-type="table"}). The Palermo replication cohort included eight patients with FCS and eight patients with MCS ([Table 1](#t0005){ref-type="table"}).Table 1Hypertriglyceridaemic patients: genotypes found in the different cohorts.Table 1**FCSMCSHo LPLComp He LPLHo not LPLComp He not LPLWT low LPL activityHePolWTNA**Montreal157102Lyon3111855Rome8152114Palermo6021232[^1]

2. Experimental design, materials and methods {#s0010}
=============================================

The items of the FCS score were selected on a pragmatic basis following discussion within a panel of experts. The relative weight of each item was set up also on a pragmatic basis. The cut-off was determined from a validation cohort and tested on replication cohorts. FCS patients were defined as any patient carrier of a homozygous or a compound heterozygous loss of function mutation in lipoprotein lipase (*LPL*), apolipoprotein C2 (*APOC2*), apolipoprotein A5 (*APOA5*), glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (*GPIHBP1*) and lipase maturation factor 1 (*LMF1*) genes or a low post-heparin LPL activity. MCS patients were defined as patients with documented history of plasma triglyceride (TG) \>10 mmol/L and carriers of either a heterozygous loss of function mutation and/or variants associated with increased TG level in *LPL, APOC2, APOA5, GPIHBP1* and *LMF1* genes.

In the patients with MCS, due to the retrospective design, the plasma TG concentration was considered to be consistently \>10 mmol/L in order to challenge the specificity of the FCS score, if not enough information was available in the medical file regarding the reproducibility of the plasma TG concentration \>10 mmol/L. Further study is needed to prospectively validate the score in cohorts with comprehensive phenotype available.

All the patients gave written, informed consent for genotyping. All the French patients received written information regarding the study according to the French bioethics Law Jardé 2017.
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=============================================
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Transparency data associated with this article can be found in the online version at <https://doi.org/10.1016/j.dib.2018.10.125>.

[^1]: FCS, familial chylomicronaemia syndrome; MCS, multifactorial chylomicronaemia syndrome; Ho, homozygous; LPL, lipoprotein lipase; Comp, compound; He, heterozygous; WT, wild type; Pol, multiple functional SNPs; NA, not available.
